CAMBRIDGE, Mass., Sept. 9, 2014 (GLOBE NEWSWIRE) -- Blueprint Medicines today announced that members of the Company's senior management team will participate in the Morgan Stanley Global Healthcare Conference 2014 on Wednesday, September 10, 2014 in New York, NY.
About Blueprint Medicines
Blueprint Medicines is a patient-driven oncology company developing highly selective kinase inhibitors for genomically defined cancer patients. Led by a management team and advisors with world renowned expertise in cancer genomics, drug discovery, and clinical oncology, Blueprint has developed a platform that combines genomics with a novel small molecule library of kinase inhibitors, enabling Blueprint to rapidly develop potent, highly selective compounds against clear genomic driver targets. Founded in 2011, Blueprint is privately held and initially backed by Third Rock Ventures and Fidelity BioSciences. For more information, please visit BlueprintMedicines.com.